Drugs show promise for childhood brain tumors, ovarian cancer

An experimental drug has shown promise in treating malignant brain tumors in children, a small study unveiled at the annual American Society of Clinical Oncology conference showed Sunday.

The early stage trial tested the effects of GDC-0449 on drug-resistant medulloblastomas, the most common form of brain tumor found in children.

Developed by US biotech firms Curis and Genentec, the latter owned by Swiss pharmaceutical group Roche since 2009, the drug works by blocking the so-called "Hedgehog" pathway.

The pathway is key to regulating cell growth and is implicated in around 20 percent of medulloblastomas, as well as other cancers.

The trial involved just 13 children, 12 of whom tolerated the drug without any significant side effects. One of the children in the trial went a year on the drug without any tumor progression.

In a previous case, a young adult with medulloblastoma experienced a similarly positive result, according to Amar Gajjar, director of the Neuro-Oncology Division at St. Jude's Children's Research Hospital in Tennessee and lead investigator in the research.

"Some patients have remained on this trial for extended periods of time, and our early results are positive and encouraging," he said at a press conference during the annual meeting of cancer researchers.

"The trend in treating children with these cancers is toward targeted therapies like this one, which block key signaling pathways and disable the cancer's ability to function or reproduce," he added.

Another study presented Sunday showed new ways to slow the return of certain types of ovarian cancer in women who have undergone chemotherapy.

The research analyzed the effect of giving a drug called Avastin to women suffering from advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer.

The drug, known generically as bevacizumab, works by blocking the development of blood vessels that can promote tumor growth.

"This is the first time a Phase III trial has demonstrated that an anti-angiogenic agent improved progression-free survival in women with this very hard-to-treat-disease," said Robert Burger of the Fox Chase Cancer Center in Philadelphia, who led the research.

"Based on the results of this... trial, bevacizumab is an acceptable initial treatment option for patients with advanced ovarian, primary peritoneal and fallopian tube cancers," said Burger.

Avastin is sold by US firm Genetech, part of Swiss pharmaceutical group Roche and has already been authorized by the US Food and Drug Administration for use in treating cancers including colon, breast, kidney, brain and lung.

Previous small-scale clinical studies involving Avastin had shown the drug's potential for ovarian cancer patients, but this trial involved an international pool of 1,873 women with newly-diagnosed advanced stage ovarian, primary peritoneal or fallopian tube cancer.

The women had all undergone surgery to remove as much of the tumor as possible, and were assigned to one of three groups.

The first received standard chemotherapy supplemented with a placebo and then received a placebo for follow-up medicine; the second received chemotherapy plus Avastin and a placebo follow-up drug; the third received chemotherapy plus Avastin and also took Avastin to follow-up.

Those in the final group had a median recurrence-free survival rate of 14.1 months, compared with the 10.3 month rate among those who received chemotherapy alone - a statistically significant difference.

The difference between the third group and those who only took Avastin during chemotherapy was judged statistically insignificant.

Ovarian cancer affects some 230,000 women each year, killing around 140,000. It is the eighth most deadly cancer among women.

ebooks
ebookA delicious collection of 50 meaty main courses
Life and Style
ebookNow available in paperback
  • Get to the point
Latest stories from i100
Have you tried new the Independent Digital Edition apps?

ES Rentals

    Independent Dating
    and  

    By clicking 'Search' you
    are agreeing to our
    Terms of Use.

    iJobs Job Widget
    iJobs General

    Ashdown Group: IT Project Coordinator (Software Development) - Kingston

    £45000 - £50000 per annum: Ashdown Group: IT Project Coordinator (Software Dev...

    Ashdown Group: Editor-in-chief - Financial Services - City, London

    £60000 - £70000 per annum + benefits : Ashdown Group: A highly successful, glo...

    Ashdown Group: Junior Application Support Analyst - Fluent German Speaker

    £25000 - £30000 per annum + benefits: Ashdown Group: A global leader operating...

    Ashdown Group: Accountant - London - £48,000 - 12 month FTC

    £40000 - £48000 per annum + bonus + benefits: Ashdown Group: International Acc...

    Day In a Page

    General Election 2015: Ed Miliband's unlikely journey from hapless geek to heart-throb

    Miliband's unlikely journey from hapless geek to heart-throb

    He was meant to be Labour's biggest handicap - but has become almost an asset
    General Election 2015: A guide to the smaller parties, from the the National Health Action Party to the Church of the Militant Elvis Party

    On the margins

    From Militant Elvis to Women's Equality: a guide to the underdogs standing in the election
    Amr Darrag: Ex-Muslim Brotherhood minister in exile still believes Egypt's military regime can be replaced with 'moderate' Islamic rule

    'This is the battle of young Egypt for the future of our country'

    Ex-Muslim Brotherhood minister Amr Darrag still believes the opposition can rid Egypt of its military regime and replace it with 'moderate' Islamic rule, he tells Robert Fisk
    Why patients must rely less on doctors: Improving our own health is the 'blockbuster drug of the century'

    Why patients must rely less on doctors

    Improving our own health is the 'blockbuster drug of the century'
    Sarah Lucas is the perfect artist to represent Britain at the Venice Biennale

    Flesh in Venice

    Sarah Lucas has filled the British pavilion at the Venice Biennale with slinky cats and casts of her female friends' private parts. It makes you proud to be a woman, says Karen Wright
    11 best anti-ageing day creams

    11 best anti-ageing day creams

    Slow down the ageing process with one of these high-performance, hardworking anti-agers
    Juventus 2 Real Madrid 1: Five things we learnt, including Iker Casillas is past it and Carlos Tevez remains effective

    Juventus vs Real Madrid

    Five things we learnt from the Italian's Champions League first leg win over the Spanish giants
    Ashes 2015: Test series looks a lost cause for England... whoever takes over as ECB director of cricket

    Ashes series looks a lost cause for England...

    Whoever takes over as ECB director of cricket, says Stephen Brenkley
    Fishing for votes with Nigel Farage: The Ukip leader shows how he can work an audience as he casts his line to the disaffected of Grimsby

    Fishing is on Nigel Farage's mind

    Ukip leader casts a line to the disaffected
    Who is bombing whom in the Middle East? It's amazing they don't all hit each other

    Who is bombing whom in the Middle East?

    Robert Fisk untangles the countries and factions
    China's influence on fashion: At the top of the game both creatively and commercially

    China's influence on fashion

    At the top of the game both creatively and commercially
    Lord O’Donnell: Former cabinet secretary on the election and life away from the levers of power

    The man known as GOD has a reputation for getting the job done

    Lord O'Donnell's three principles of rule
    Rainbow shades: It's all bright on the night

    Rainbow shades

    It's all bright on the night
    'It was first time I had ever tasted chocolate. I kept a piece, and when Amsterdam was liberated, I gave it to the first Allied soldier I saw'

    Bread from heaven

    Dutch survivors thank RAF for World War II drop that saved millions
    Britain will be 'run for the wealthy and powerful' if Tories retain power - Labour

    How 'the Axe' helped Labour

    UK will be 'run for the wealthy and powerful' if Tories retain power